Neutral glycosphingolipids in human blood: A precise mass spectrometry analysis with special reference to lipoprotein-associated Shiga toxin receptors

Journal of Lipid Research

Volumn 51, Issue 8, 2010, Pages 2282-2294

  Schweppe, Christian H ^a   Hoffmann, Petra ^a   Nofer, Jerzy Roch ^a   Pohlentz, Gottfried ^a   Mormann, Michael ^a   Karch, Helge ^a   Friedrich, Alexander W ^a   Müthing, Johannes ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Galactosylceramide; Globotriaosylceramide; Glucosylceramide; Glycolipids; Monohexosylceramides

Indexed keywords

CERAMIDE DERIVATIVE; FATTY ACID; GALACTOSYLCERAMIDE; GLOBOTRIAOSYLCERAMIDE; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; HIGH DENSITY LIPOPROTEIN; LACTOSYLCERAMIDE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VEROTOXIN 1; VEROTOXIN 2; VERY LOW DENSITY LIPOPROTEIN; ANTIBODY; CERAMIDE MONOHEXOSIDE; CERAMIDE TRIHEXOSIDE; CEREBROSIDE; GANGLIO-N-TRIAOSYLCERAMIDE; GANGLIOSIDE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HYDROXYLATION; MASS SPECTROMETRY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; QUADRUPOLE MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; THIN LAYER CHROMATOGRAPHY; TIME OF FLIGHT MASS SPECTROMETRY; BLOOD; BLOOD ANALYSIS; CHEMISTRY; IMMUNOASSAY; IMMUNOLOGY; PROCEDURES; STANDARD; STANDARDS;

ANTIBODIES; BLOOD CHEMICAL ANALYSIS; CEREBROSIDES; CHROMATOGRAPHY, THIN LAYER; GANGLIOSIDES; HUMANS; IMMUNOASSAY; LIPOPROTEINS; MASS SPECTROMETRY; NEUTRAL GLYCOSPHINGOLIPIDS; REFERENCE STANDARDS; TRIHEXOSYLCERAMIDES;

EID: 77956839918     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M006759     Document Type: Article

References (78)

1. Levery, S. B. 2005. Glycosphingolipid structural analysis and glycosphingolipidomics. Methods Enzymol. 405: 300-369.
2. Müthing, J., and U. Distler. 2010. Advances on the compositional analysis of glycosphingolipids combining thin-layer chromatography with mass spectrometry. Mass Spectrom. Rev. 29: 425-479.
3. Pruett, S. T., A. Bushnev, K. Hagedorn, M. Adiga, C. A. Haynes, M. C. Sullards, D. C. Liotta, and A. H. Merrill, Jr. 2008. Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols. J. Lipid Res. 49: 1621-1639.
4. Merrill, A. H., Jr., T. H. Stokes, A. Momin, H. Park, B. J. Portz, S. Kelly, E. Wang, M. C. Sullards, and M. D. Wang. 2009. Sphingolipidomics; a valuable tool to understanding the roles of sphingolipids in biology and disease. J. Lipid Res. 50: S97-S102.
5. Sonnino, S., A. Prinetti, L. Mauri, V. Chigorno, and G. Tettamanti. 2006. Dynamic and structural properties of sphingolipids as driving forces for the formation of membrane domains. Chem. Rev. 106: 2111-2125.
6. Pike, L. J. 2009. The challenge of lipid rafts. J. Lipid Res. 50: S323-S328.
7. Ledeen, R. W., and G. Wu. 2008. Nuclear sphingolipids: metabolism and signalling. J. Lipid Res. 49: 1176-1186.
8. Lopez, P. H., and R. L. Schnaar. 2009. Gangliosides in cell recognition and membrane protein regulation. Curr. Opin. Struct. Biol. 19: 549-557.
9. Ariga, T., M. P. McDonald, and R. K. Yu. 2008. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease-a review. J. Lipid Res. 49: 1157-1175.
10. Yu, R. K., Y. Nakatami, and M. Yanagisawa, M. 2009. The role of glycosphingolipid metabolism in the developing brain. J. Lipid Res. 50: S440-S445.
11. Karlsson, K. A. 1989. Animal glycosphingolipids as membrane attachment sites for bacteria. Annu. Rev. Biochem. 58: 309-350.
12. Smith, D. C., J. M. Lord, L. M. Roberts, and L. Johannes. 2004. Glycosphingolipids as toxin receptors. Semin. Cell Dev. Biol. 15: 397-408.
13. Müthing, J., C. H. Schweppe, H. Karch, and A. W. Friedrich. 2009. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb. Haemost. 101: 252-264.
14. Sandvig, K. 2001. Shiga toxins. Toxicon. 39: 1629-1635.
15. Karch, H., P. I. Tarr, and M. Bielaszewska. 2005. Enterohaemorrhagic Escherichia coli in human medicine. Int. J. Med. Microbiol. 295: 405-418.
16. 3. Biochemistry. 37: 1777-1788.
17. Bielaszewska, M., and H. Karch. 2005. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb. Haemost. 94: 312-318.
18. Sandvig, K., Ø. Garred, K. Prydz, J. V. Kozlov, S. H. Hansen, and B. van Deurs. 1992. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature. 358: 510-512.
19. Endo, Y., K. Tsurugi, T. Yutsudo, Y. Takeda, T. Ogasawara, and K. Igarashi. 1988. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and Shiga toxin on eukaryotic ribosomes. Eur. J. Biochem. 171: 45-50.
20. Garred, Ø., B. van Deurs, and K. Sandvig. 1995. Furin-induced cleavage and activation of Shiga toxin. J. Biol. Chem. 270: 10817-10821.
21. Proulx, F., E. G. Seidman, and D. Karpman. 2001. Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. Pediatr. Res. 50: 163-171.
22. Tarr, P. I., C. A. Gordon, and W. L. Chandler. 2005. Shiga-toxin- producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 365: 1073-1086.
23. Ståhl, A. L., L. Sartz, A. Nelsson, Z. D. Békássy, and D. Karpman. 2009. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in haemolytic uremic syndrome. PLoS One. 4: e6990.
24. Hurley, B. P., C. M. Thorpe, and D. W. Acheson. 2001. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect. Immun. 69: 6148-6155.
25. Holgersson, J., P. Å. Jovall, and M. E. Breimer. 1991. Glycosphingolipids of human large intestine: detailed structural characterization with special reference to blood group compounds and bacterial receptor structures. J. Biochem. 110: 120-131.
26. Brigotti, M., A. Caprioli, A. E. Tozzi, P. L. Tazzari, F. Ricci, R. Conte, D. Carnicelli, M. A. Procaccino, F. Minelli, A. V. S. Ferretti, et al. 2006. Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome. J. Clin. Microbiol. 44: 313-317.
27. Brigotti, M., D. Carnicelli, E. Ravanelli, S. Barbieri, F. Ricci, A. Bontadini, A. E. Tozzi, G. Scavia, A. Caprioloi, and P. L. Tazzari. 2008. Interactions between Shiga toxins and human polymorphonuclear leukocytes. J. Leukoc. Biol. 84: 1019-1027.
28. Chatterjee, S., and P. O. Kwiterovich, Jr. 1984. Glycosphingolipids and plasma lipoproteins: a review. Can. J. Biochem. Cell Biol. 62: 385-397.
29. Lingwood, C. A. 1996. Role of verotoxin receptors in pathogenesis. Trends Microbiol. 4: 147-153.
30. Dawson, G., A. W. Kruski, and A. M. Scanu. 1976. Distribution of glycosphingolipids in the serum lipoproteins of normal human subjects and patients with hypo- and hyperlipidemias. J. Lipid Res. 17: 125-131.
31. Kundu, S. K., I. Diego, S. Osovitz, and D. M. Marcus. 1985. Glycosphingolipids of human plasma. Arch. Biochem. Biophys. 238: 388-400.
32. 31P-NMR. J. Lipid Res. 42: 1501-1508.
33. Sommer, U., H. Herscovitz, F. K. Welty, and C. E. Costello. 2006. LC-MS-based method for qualitative and quantitative analysis of complex lipid mixtures. J. Lipid Res. 47: 804-814.
34. Smith, D. C., D. J. Sillence, T. Falguières, R. M. Jarvis, L. Johannes, J. M. Lord, F. M. Platt, and L. M. Roberts. 2006. The association of Shiga-like toxin with detergent-resistant membranes is modulated by glucosylceramide and is an essential requirement in the endoplasmic reticulum for a cytotoxic effect. Mol. Biol. Cell. 17: 1375-1387.
35. Deguchi, H., J. A. Fernández, I. Pabinger, J. A. Heit, and J. H. Griffin. 2001. Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood. 97: 1907-1914.
36. Fantini, J., D. G. Cook, N. Nathanson, S. L. Spitalnik, and F. Gonzalez-Scarano. 1993. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc. Natl. Acad. Sci. USA. 90: 2700-2704.
37. Alfsen, A., and M. Bomsel. 2002. HIV-1 gp41 envelope residues 650-685 exposed native virus act as a lectin to bind epithelial cell galactosyl ceramide. J. Biol. Chem. 277: 25649-25659.
38. Havel, R. J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
39. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
40. Ledeen, R. W., and R. K. Yu. 1982. Gangliosides: structure, isolation, and analysis. Methods Enzymol. 83: 139-191.
41. Müthing, J., H. Egge, B. Kniep, and P. F. Mühlradt. 1987. Structural characterization of gangliosides from murine T lymphocytes. Eur. J. Biochem. 163: 407-416.
42. Müthing, J., U. Maurer, K. Šoštarić, U. Neumann, H. Brandt, S. Duvar, J. Peter-Katalinić, and S. Weber-Schürholz. 1994. Differential distribution of glycosphingolipids in mouse rabbit skeletal muscle demonstrated by biochemical and immunohistological analyses. J. Biochem. 115: 64-73. (Pubitemid 24060156)
43. Smith, H. W., and M. A. Linggood. 1971. The transmissible nature of enterotoxin production in a human enteropathogenic strain of Escherichia coli. J. Med. Microbiol. 4: 301-305.
44. Strockbine, N. A., L. R. M. Marques, J. W. Newland, H. W. Smith, R. K. Holmes, and A. D. O'Brien. 1986. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect. Immun. 53: 135-140.
45. Petric, M., M. A. Karmali, S. Richardson, and R. Cheung. 1987. Purification and biological properties of Escherichia coli verotoxin. FEMS Microbiol. Lett. 41: 63-68.
46. Head, S. C., M. A. Karmali, and C. A. Lingwood. 1991. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated sub-units. J. Biol. Chem. 226: 3617-3621.
47. Kasai, M., M. Iwamori, Y. Nagai, K. Okumura, and T. Tada. 1980. A glycolipid on the surface of mouse natural killer cells. Eur. J. Immunol. 10: 175-180.
48. Chester, M. A. 1999. IUPAC-IUB Joint Commission on Biochemical Nomenclature. Nomenclature of glycolipids. Recommendations 1997. Glycoconj. J. 16: 1-6.
49. Saito, T., and S. I. Hakomori. 1971. Quantitative isolation of total glycosphingolipids from animal cells. J. Lipid Res. 12: 257-259.
50. Meisen, I., A. W. Friedrich, H. Karch, U. Witting, J. Peter-Katalinić, and J. Müthing. 2005. Application of combined high-performance thin-layer chromatography immunostaining and nanoelectrospray ionisation quadrupole time-of-flight tandem mass spectrometry to the structural characterization of high- and low-affinity binding ligands of Shiga toxin 1. Rapid Commun. Mass Spectrom. 19: 3659-3665.
51. Duvar, S., J. Peter-Katalinić, F. G. Hanisch, and J. Müthing. 1997. Isolation and structural characterization of glycosphingolipids of in vitro propagated bovine aortic endothelial cells. Glycobiology. 7 1099-1109. (Pubitemid 28015799)
52. Kean, E. L. 1966. Separation of gluco- and galactocerebrosides by means of borate thin-layer chromatography. J. Lipid Res. 7: 449-452.
53. Skipski, V. P. 1975. Thin-layer chromatography of neutral glycosphingolipids. Methods Enzymol. 35: 396-425.
54. Meisen, I., J. Peter-Katalinić, and J. Müthing. 2004. Direct analysis of silica gel extracts from immunostained glycosphingolipids by nanoelectrospray ionization quadrupole time-of-flight mass spectrometry. Anal. Chem. 76: 2248-2255.
55. Müthing, J. 1998. TLC in structure and recognition studies of glycosphingolipids. In Methods in Molecular Biology. E. F. Hounsell, editor. Humana Press Inc., Totawa, NJ. 183-195.
56. Müthing, J., S. Duvar, D. Heitmann, F. G. Hanisch, U. Neumann, G. Lochnit, R. Geyer, and J. Peter-Katalinić. 1999. Isolation and structural characterization of glycosphingolipids of in vitro propagated human umbilical vein endothelial cells. Glycobiology. 9 459-468. (Pubitemid 29240343)
57. Distler, U., M. Hülsewig, J. Souady, K. Dreisewerd, J. Haier, N. Senninger, A. W. Friedrich, H. Karch, F. Hillenkamp, S. Berkenkamp, et al. 2008. Matching IR-MALDI-o-TOF mass spectrometry with the TLC overlay binding assay and its clinical application for tracing tumor-associated glycosphingolipids in hepatocellular and pancreatic cancer. Anal. Chem. 80: 1 835-1846.
58. Schweppe, C. H., M. Bielaszewska, G. Pohlentz, A. W. Friedrich, H. Büntemeyer, M. A. Schmidt, K. S. Kim, J. Peter-Katalinić, H. Karch, and J. Müthing. 2008. Glycosphingolipids in vascular endothelial cells: relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity. Glycoconj. J. 25: 291-304.
59. Distler, U., J. Souady, M. Hülsewig, I. Drmić-Hofman, J. Haier, A. W. Friedrich, H. Karch, N. Senninger, K. Dreisewerd, S. Berkenkamp, et al. 2009. Shiga toxin receptor Gb3Cer/CD77: tumor association and promising therapeutic target in pancreas and colon cancer. PLoS One. 4: e6813.
60. Meisen, I., J. Peter-Katalinić, and J. Müthing. 2003. Discrimination of neolacto-series gangliosides with α2-3- and α2-6-linked N-acetylneuraminic acid by nanoelectrospray ionization low-energy collision-induced dissociation tandem quadrupole TOF MS. Anal. Chem. 75: 5719-5725.
61. Domon, B., and C. E. Costello. 1988. A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. Glycoconj. J. 5: 397-409.
62. Domon, B., and C. E. Costello. 1988. Structure elucidation of glycosphingolipids and gangliosides using high-performance tandem mass spectrometry. Biochemistry. 27: 1534-1543.
63. Adams, J., and Q. Ann. 1993. Structure determination of sphingolipids by mass spectrometry. Mass Spectrom. Rev. 12: 51-85.
64. Chatterjee, S., W. R. Bell, and P. O. Kwiterovich, Jr. 1984 Distribution of antithrombin III and glucosylceramide in human plasma lipoproteins and lipoprotein deficient plasma. Lipids. 19: 363-366.
65. Dasgupta, S., S. B. Levery, and E. L. Hogan. 2002. 3- O -acetylsphingosine series myelin glycolipids: characterization of novel 3- O -acetyl-sphingosine galactosylceramide. J. Lipid Res. 43: 751-761.
66. + adducts. J. Mass Spectrom. 42: 598-620.
67. Shaner, R. L., J. C. Allegood, H. Park, E. Wang, S. Kelly, C. A. Haynes, M. C. Sullards, and A. H. Merrill, Jr. 2009. Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers. J. Lipid Res. 50: 1692-1707.
68. Han, X., and H. Cheng. 2005. Characterization and direct quantitation of cerebroside molecular species from lipid extracts by shotgun lipidomics. J. Lipid Res. 46: 163-175. (Pubitemid 40066682)
69. + adducts. J. Mass Spectrom. 42: 598-620.
70. Zama, K., Y. Hayashi, S. Ito, Y. Hirabayashi, T. Inoue, K. Ohno, N. Okino, and M. Ito. 2009. Simultaneous quantification of glucosylceramide and galactosylceramide by normal-phase HPLC using O-phthalaldehyde derivatives prepared with sphingolipid ceramide N-deacylase. Glycobiology. 19: 767-775.
71. Blasiole, D. A., R. A. Davis, and A. D. Attie. 2007. The physiological and molecular regulation of lipoprotein assembly and secretion. Mol. Biosyst. 3: 608-619.
72. Memon, R. A., W. M. Holleran, A. H. Moser, T. Seki, Y. Uchida, J. Fuller, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 1998. Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produces lipoproteins enriched in ceramides and sphingomyelin. Arterioscler. Thromb. Vasc. Biol. 18: 1257-1265.
73. Khovidhunkit, W., M. S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld. 2004. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45: 1169-1196.
74. Field, F. J., and S. N. Mathur. 1995. Intestinal lipoprotein synthesis and secretion. Prog. Lipid Res. 34: 185-198.
75. Hoofnagle, A. N., and J. W. Heinecke. 2009. Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins. J. Lipid Res. 50: 1967-1975.
76. Loeb, J. A., and G. Dawson. 1982. Reversible exchange of glycosphingolipids between human high and low density lipoproteins. J. Biol. Chem. 257: 11982-11987.
77. Fishman, P. H., R. M. Bradley, J. Moss, and V. C. Manganiello. 1978. Effect of serum on ganglioside uptake and choleragen responsiveness of transformed mouse fibroblasts. J. Lipid Res. 19: 77-81.
78. Karmali, M. A. 2004. Prospects for preventing serious systemic toxemic complications of Shiga toxin producing Escherichia coli infections using Shiga toxin receptor analogues. J. Infect. Dis. 189: 355-359.